Mesoblast completes patient recruitment for phase 3 chronic back pain trial

April 28, 2026 8:53 PM

Mesoblast Limited (NASDAQ: MESO; ASX: MSB) announced that its phase 3 clinical trial evaluating rexlemestrocel-L for chronic low back pain ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found